Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode the science-heavy language in BeiGene’s oncology disclosures? Each 10-K details dozens of global clinical trials, milestone obligations, and R&D burn-rates that can stretch past 300 pages. Finding when cash runs out—or which trial just moved to Phase III—takes time investors rarely have.
Stock Titan solves that problem. Our AI-powered summaries turn BeiGene SEC filings explained simply, highlighting the exact paragraph that answers questions like “How much did R&D rise this quarter?” or “Which licensing partner triggered a milestone?” Whether you need the BeiGene annual report 10-K simplified, a BeiGene quarterly earnings report 10-Q filing, or BeiGene 8-K material events explained, the platform delivers real-time alerts the moment they hit EDGAR. You’ll also see BeiGene Form 4 insider transactions real-time, complete with context so you understand why an executive sold shares before a data readout.
Dig deeper without getting lost: track BeiGene insider trading Form 4 transactions to spot buying trends, scan BeiGene proxy statement executive compensation to evaluate alignment, and run instant BeiGene earnings report filing analysis to compare pipeline spending quarter-over-quarter. From understanding BeiGene SEC documents with AI to monitoring BeiGene executive stock transactions Form 4, every filing type is covered and linked to the metrics that matter—so you make informed decisions faster.
BeOne Medicines Ltd. has fully repaid and terminated a major credit facility with China Merchants Bank Co., Ltd. The company used a portion of the borrowings from its previously disclosed Facilities Agreement, arranged with The Hongkong and Shanghai Banking Corporation Limited and other lenders, to pay off all outstanding amounts under the prior CMB Credit Facility.
As part of this repayment, all commitments by China Merchants Bank to extend further credit, as well as all guarantees and security interests granted by BeOne Medicines under the CMB Credit Facility, were terminated. The company incurred no termination penalties in connection with ending this facility.
BeOne Medicines Ltd. appointed Dr. Lai Wang as President, Global Head of Research and Development, effective January 1, 2026. In this expanded role, he will lead research and development as well as other functions, including business development and alliance management.
Dr. Wang, age 48, has led the Company’s R&D since April 2021 after joining in 2011, and previously served as Director of Research at Joyant Pharmaceuticals. His new compensation includes a $750,000 annual salary, an annual target bonus equal to 75% of base salary, and a one-time equity incentive of $10,000,000 in restricted share units vesting in four equal annual installments, with certain accelerated vesting rights under his employment agreement. The Company states there are no related-party or other arrangements connected to his appointment.
BeOne Medicines Ltd. chief executive officer and director reported sales of American Depositary Shares in mid-December 2025 under a pre-arranged Rule 10b5-1 trading plan.
The Form 4 discloses multiple sales of American Depositary Shares on 12/15/2025 and 12/16/2025 at weighted average prices listed in the report, with each American Depositary Share representing 13 ordinary shares. Following these transactions, the reporting person holds 0 American Depositary Shares directly but continues to beneficially own 5,141,041 ordinary shares directly and additional ordinary shares through various trusts and entities, with certain indirect interests expressly disclaimed as beneficial ownership.
BeOne Medicines Ltd. director reports option exercise and ADS sales. On 11/26/2025, the reporting director exercised a share option covering 34,151 ordinary shares at an exercise price of
ONC filed a Form 144 indicating that stockholder Xiaobin Wu plans to sell 3,991 shares of common stock through Morgan Stanley Smith Barney LLC on or about 11/17/2025, with an aggregate market value of $1,518,302.91. The shares are listed on NASDAQ, and the issuer reports 109,663,273 common shares outstanding.
The seller acquired 1,238 and 2,753 common shares through restricted stock vesting under a registered plan in June 2025. Over the past three months, the seller reported additional sales of 6,009 and 10,000 common shares, with gross proceeds of $2,286,659.45 and $3,560,160.50, respectively.
BeOne Medicines Ltd. (ONC) reported insider transactions by its President and COO. The reporting person sold 16,009 American Depositary Shares (ADS) on 11/12/2025 and 11/13/2025 at weighted average prices with trade ranges from $350.00 to $381.50, as detailed in the footnotes.
After these sales, the reporting person held 0 ADS directly. Beneficial ownership also includes 1,020,861 ordinary shares and 4,000 ADS held indirectly by spouse. Each ADS represents 13 ordinary shares. One footnote states that the ordinary share total includes 650 ordinary shares acquired under the company’s employee share purchase plan.
BeOne Medicines (ONC) reported insider activity by its SVP, General Counsel. On 11/12/2025, the officer exercised share options into 996 American Depositary Shares (ADS), which equals 12,948 Ordinary Shares (each ADS represents 13 Ordinary Shares), and sold 996 ADS pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
The ADS sales were executed at $348.75 (664 ADS) and $350 (332 ADS). Following these transactions, the reporting person beneficially owned 223,106 Ordinary Shares directly. The option exercises reflected exercise prices represented in Ordinary Shares of $14.96, $16.41, and $12.23, respectively.
BeOne Medicines (ONC) reported insider activity by its Chief Executive Officer and Director. The reporting person made two bona fide gifts of ordinary shares: 151,320 shares on 11/11/2025 and 858,533 shares on 11/12/2025, for a combined 1,009,853 shares, each at a stated price of $0 per footnote (gift). After these transactions, direct beneficial ownership stood at 6,441,041 ordinary shares.
The filing also lists indirect holdings, including 481,533 (P&O Trust), 7,722,480 (a grantor retained annuity trust), 28,204,115 (Oyler Investment LLC), 9,545,000 (Roth IRA), and 102,188 (The John Oyler Legacy Trust), as described in the footnotes with certain beneficial ownership disclaimers. No derivative securities were reported.
ONC: A shareholder filed a Form 144 notice to sell up to 6,009 shares of common stock, with an aggregate market value of $2,286,659.45. The filer lists Morgan Stanley Smith Barney LLC as broker, an approximate sale date of November 13, 2025, and the NASDAQ as the exchange.
The notice shows shares were acquired via restricted stock vesting under a registered plan on multiple dates. The table also reports 109,663,273 shares outstanding. Recent activity by the same seller over the past three months includes sales of 49,858 shares on August 13, 2025 for $15,162,320.35, 39,936 shares on August 14, 2025 for $12,180,813.46, and 10,000 shares on November 12, 2025 for $3,560,160.50.
ONC — Notice of proposed insider sale under Rule 144. A selling security holder filed a Form 144 to sell 10,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value $3,560,161.00. The shares are listed on NASDAQ, with an approximate sale date of 11/12/2025.
The filing lists prior acquisitions as restricted stock vesting under a registered plan across multiple dates, including 06/17/2023 (1,456 shares), 06/22/2023 (2,118), 06/05/2023 (4,291), 03/14/2024 (59), 09/15/2023 (52), 06/16/2023 (870), and 06/15/2024 (1,154). As context, shares outstanding were 109,663,273; this is a baseline figure, not the amount being offered.
The notice also reports sales in the past three months by Xiaobin Wu: 39,936 shares on 08/14/2025 for $12,180,813.46 and 49,858 shares on 08/13/2025 for $15,162,320.35.
FAQ
What is the current stock price of BeOne Medicines Ltd. (ONC)?
What is the market cap of BeOne Medicines Ltd. (ONC)?
